基线18F-FDG PET/CT骨髓代谢对anti-PD-1治疗转移性黑色素瘤的预后价值
研究纳入92例转移性黑色素瘤患者,在anti-PD-1治疗前行18F-FDG PET/CT,测量SUVmax、代谢肿瘤体积及骨髓与肝脏SUVmean比值(BLR)。多因素分析显示BLR是PFS和OS的独立预后因素(P=0.017和P=0.011),高BLR组白细胞、中性粒细胞及C反应蛋白更高。
要点
- 基线BLR是anti-PD-1治疗转移性黑色素瘤PFS和OS的独立预后因素。
- 高BLR组白细胞计数、中性粒细胞计数及C反应蛋白水平高于低BLR组。
- 高BLR可能与系统性炎症相关,提示免疫抑制状态。
核心结论
- 高BLR与较差的无进展生存和总生存相关,可能由系统性炎症相关的免疫抑制解释。
研究设计与样本
- 回顾性分析92例转移性黑色素瘤患者,在anti-PD-1治疗开始前行基线18F-FDG PET/CT,测量SUVmax、代谢肿瘤体积和BLR。
主要发现
- 多因素分析显示BLR是PFS的独立预后因素(P=0.017)。
- 多因素分析显示BLR是OS的独立预后因素(P=0.011)。
- 高BLR组(>中位数)白细胞计数、中性粒细胞计数和C反应蛋白水平高于低BLR组(≤中位数)(P<0.05)。
关键数值与推荐
- BLR定义为骨髓与肝脏SUVmean的比值。
- 高BLR组为BLR>中位数,低BLR组为BLR≤中位数。
临床怎么用
- 基线18F-FDG PET/CT测量的BLR可作为anti-PD-1治疗转移性黑色素瘤的预后分层指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to investigate the prognostic value of 18F-FDG PET/CT parameters in melanoma patients before beginning therapy with antibodies to the programmed cell death 1 receptor (anti-PD-1). Methods: Imaging parameters including SUVmax, metabolic tumor volume, and the ratio of bone marrow to liver SUVmean (BLR) were measured from baseline PET/CT in 92 patients before the start of anti-PD-1 therapy. The association with survival and imaging parameters combined with clinical factors was evaluated. Clinical and laboratory data were compared between the high-BLR group (>median) and the low-BLR group (≤median). Results: Multivariate analyses demonstrated that BLR was an independent prognostic factor for progression-free and overall survival (P = 0.017 and P = 0.011, respectively). The high-BLR group had higher white blood cell counts and neutrophil counts and a higher level of C-reactive protein than the low-BLR group (P < 0.05). Conclusion: Patients with a high BLR were associated with poor progression-free and overall survival, potentially explained by evidence of systemic inflammation known to be associated with immunosuppression.
引用
- Nakamoto R, Zaba LC, Liang T, et al. Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. J Nucl Med. 2021. PMID: 33547210. doi:10.2967/jnumed.120.254482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。